🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Ex-drug CEO Shkreli gets green light to appear before Congress

Published 25/01/2016, 18:08
© Reuters.  Ex-drug CEO Shkreli gets green light to appear before Congress
INGA
-
TWTR
-

By Jonathan Stempel

NEW YORK (Reuters) - A federal judge on Monday gave Martin Shkreli, a former pharmaceuticals executive facing securities fraud charges, permission to appear at a Congressional hearing on drug pricing.

U.S. District Judge Kiyo Matsumoto in Brooklyn, New York modified Shkreli's bail conditions so that he may appear by subpoena before the House Committee on Oversight and Government Reform.

Shkreli has said he plans to invoke his right against self-incrimination if he attends.

The hearing has been rescheduled to Feb. 4 from Jan. 26, following this weekend's snowstorm.

Shkreli's $5 million bail package had limited his travel to New York, prompting his lawyers to seek the judge's "guidance" on how their client could comply with the subpoena.

In her order, Matsumoto admonished the lawyers that she "does not condone correspondence 'seek (ing) the Court's guidance,'" and that similar requests must be legally supported.

Marcus Asner, a lawyer for Shkreli, did not immediately respond to requests for comment.

Shkreli, 32, stepped down last month as chief executive of Turing Pharmaceuticals Inc following his arrest for allegedly defrauding investors in two hedge funds he once ran.

The House committee has said it wants to hear Shkreli discuss Turing's decision to boost by more than 5,000 percent the price of Daraprim, which has been used for decades to treat a potentially deadly parasitic infection.

Shkreli has achieved a degree of notoriety for defending the price hike, and for a brashness that has included maintaining an active presence online, including on Twitter (N:TWTR), even after the criminal charges were announced.

While the criminal case is unrelated to Turing, Shkreli's lawyers have expressed concern that letting their client testify may expose him to criminal liability.

Citing his lawyers' advice, Shkreli said in an unsworn declaration on Jan. 21 that he will say nothing to Congress "other than to identify myself and then assert the Fifth Amendment Privilege," or the constitutional protection against self-incrimination.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.